NCT07727629尚未招募1 期
A Randomized, Open-label, Multiple-dose, Crossover Phase 1 Clinical Trial to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics Characteristics After Oral Administration of UI059 and UIC202201 in Healthy Adult Volunteers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- AUCτ,ss
研究概览
简要总结
A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult volunteers aged 19 years or older at the time of screening.
- •Weight and Body Mass Index (BMI) at screening as follows:
- •Body weight: ≥50.0kg for males, ≥45.0kg for females.
- •BMI: ≥18.0mg/m2 and ≤ 30.0kg/m2
- •Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings based on medical examination.
- •Subjects judged suitable for the clinical trial based on laboratory tests, vital signs, physical examination, and 12-lead ECG conducted at screening.
- •Subjects who test negative for H.pylori antibody at screening.
- •Subjects who voluntarily decide to participate and provide written informed consent after being fully informed of and understanding the details of this clinical trial and the subject compliance requirements.
排除标准
- •Current or past history of clinically significant liver, kidney, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal diseases.
- •History of gastrointestinal diseases (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis) or gastrointestinal surgery (excluding simple appendectomy, hernia repair, or dental procedures) that may affect the absorption of the investigational product.
- •Pregnant (positive Urine-HCG test) or breastfeeding women.
- •History of clinically significant hypersensitivity (e.g., anaphylaxis or angioedema) to the investigational product ingredients, excipients, or other drugs (e.g., aspirin, penicillin-type antibiotics, macrolide antibiotics, etc.).
- •Clinically significant findings on 12-lead ECG at screening, including:
- •QTc>450ms(males) or >470ms(females)
- •PR intervals>200ms
- •QRS duration>120ms
- •Clinically significant laboratory results at screening, including:
- •Liver function (AST, ALT, ALP, γ-GT, and total bilirubin) exceeding 2 times the upper limit of normal (ULN).
- •Serum creatinine outside the reference range, or eGFR calculated by the CKD-EPI formula < 60 mL/min/1.73m
- •History of drug abuse or a positive response to drugs of abuse in the urine drug screen.
- •Vital signs measured in a sitting position after at least 3 minutes of rest at screening:
- •Systolic Blood Pressure ≤ 90 mmHg or ≥ 150 mmHg
- •Diastolic Blood Pressure ≤ 60 mmHg or ≥ 100 mmHg
- •Pulse Rate ≤ 40 bpm or ≥ 100 bpm
- •Abnormal diet or consumption of food that may affect the absorption, distribution, metabolism, and excretion (ADME) of the investigational product.
- •Use of any prescription drugs or herbal medicines within 2 weeks, or any over-the-counter (OTC) drugs or health functional foods within 10 days before the first dose (unless deemed by the investigator not to affect the PK of the investigational product).
- •Use of drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose.
- •Participation and dosing in another clinical trial within 6 months before the first dose.
- •Whole blood donation within 2 months, component donation within 1 month, or blood transfusion within 1 month before the first dose; or inability to refrain from donation during the study.
- •Consistent alcohol consumption exceeding 21 units/week (1 unit = 10g of pure alcohol) within 6 months before the first dose, or inability to abstain from alcohol during the study.
- •Smokers who averaged > 10 cigarettes/day within 3 months before the first dose, or inability to quit smoking from 48 hours before the first dose until the last PK blood collection.
- •Consumption of food containing grapefruit within 72 hours before the first dose, or inability to abstain during the study.
- •Consumption of food containing caffeine (coffee, tea, soda, etc.) from 48 hours before each first dose until the last PK blood collection, or inability to abstain.
- •Strenuous exercise exceeding normal daily activities within 72 hours before the first dose, or inability to refrain from such exercise.
- •Subjects (or their partners) planning pregnancy, or those not using medically accepted methods of contraception (e.g., hormonal contraceptives, IUD, sterilization, barrier methods) from the time of consent until 2 weeks after the last dose.
- •Any other reason the investigator deems the subject unsuitable for participation in the clinical trial.
结局指标
主要结局
AUCτ,ss
时间窗: day1: 0-24 hours / day 5, day 6: 0 hour / day 7: 0-24 hours
Percent decrease from baseline in integrated gastric acidity
时间窗: Day -1(0 hour) - Day 1(0 hour) / Day1(0 hour) - Day2(0 hour) / Day7(0 hour) - Day7(24 hour)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
An Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer CachexiaCancer CachexiaNCT07584057Yunnan Baiyao Group Co., Ltd.146
招募中
2 期
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.NCT07635563Incannex Healthcare Ltd120
招募中
1 期
A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male ParticipantsHealthy Male AdultsFood Effect in Healthy VolunteersNCT07549919AnnJi Pharmaceutical Co., Ltd.26
尚未招募
1 期
QLF4113 in Participants With Metastatic Prostate CancerProstate CancerNCT07636707Qilu Pharmaceutical Co., Ltd.140
招募中
1 期
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid TumorsNCT07380334Jiangsu HengRui Medicine Co., Ltd.200